WASHINGTON: Healthcare communicators are concerned that a Food and Drug Administration letter criticizing a pharmaceutical company's PR pitch may change the way agencies and their pharma clients promote products.
The FDA sent the letter to Cornerstone Therapeutics, a specialty pharmaceutical company, late last month criticizing a PR pitch sent on behalf of the company by Fleishman-Hillard. The federal agency considered the pitch “false or misleading because it omits important risk information” about its Curosuf product, which is used for rescue ...